Redeye gives an initial take on the announced Q1 royalties for Leqembi.
123f started FY26 on a resilient note, delivering Q1 sales of € 6.
Redeye comments on CombinedX’s Q1 2026 report, which delivered a 9% EBITA beat against our estimates...
Gapwaves reported Q1 net sales of SEK18.8m, down 17% y/y and ~25% below Redeye's estimate of SEK25.
Solteq's Q1 fell short on weak R&C, yet guidance was reiterated and the 2026 recovery rests on cost ...
Suominen reports Q1 results on May 7. There’s a lot of room to improve from the low comparison figur...
Consti Q1 report showed signs of improvement in the Services business supported by tight cost contro...
* '26e-'28e adj. EBITA down 24-13% * Webstep issues weigh significantly on revenue * Trading at NTM ...
Yesterday, Bittium published its Q1'26 business review.
Softer sales, partly due to delays, impacted the quarter, but should point to a strong Q2.
While the Q1 report was rather undramatic, Xspray stands before potentially transformative months ah...
Redeye updates on Invisio ahead of Q1-results (due 6 May) where we expect continued YoY growth suppo...
Redeye provides a preview ahead of Fractal Gaming Group's Q1 2026 report due on 7 May.
Redeye comments on BioInvent's Q1 report 2026, which was a transitional quarter with limited news si...
Redeye takes a more positive view of Hexatronic following an, in our view, solid Q1 report, which mo...
Gofore share took a significant hit on the Q1 results, which we viewed as a small miss in EBITA.
We raise 2026E-28E adj. EPS by 9-15% after a solid Q1 and our fair value range to SEK 41-48 (39-45),...
* Has already pre-announced sales and EBIT for Q1 * We assume a recovery in sales growth in H2'26e *...
* Q1 surprised on gross margin: 45% vs. our 42% * Pricer transition a temporary drag, offset by Vusi...
* Strong Q1 beat with 110bps margin expansion on adj.
* Q1 exceeded our expectations, but limited estimate revisions * Confirms that Q4 was likely the ser...
